Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: teevee who wrote (76)	6/2/2003 1:12:34 PM
From: Icebrg	Read Replies (2) \| Respond to of 285

>>why proceed with further trials?>> Neoral over time destroys the kidneys. ISA257 is not supposed to do so. The kidney damages is however a long-term effect, that is not picked up in a short term trial like this. There are still very valid reasons to continue, but I think the side-effects - if they are experienced as serious - will be considered as negative for example by a patient with an auto-immune disease, where there are alternatives available. Erik